• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磁性纳米簇武装响应性 PD-1 抗体协同增强用于实体瘤的过继性 T 细胞疗法。

Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors.

机构信息

School of Life Science , Beijing Institute of Technology , No. 5 South Street , Zhong Guan Cun, Beijing 100081 , China.

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , 1 North Second Street , Zhong Guan Cun, Beijing 100190 , China.

出版信息

ACS Nano. 2019 Feb 26;13(2):1469-1478. doi: 10.1021/acsnano.8b07141. Epub 2019 Feb 18.

DOI:10.1021/acsnano.8b07141
PMID:30763076
Abstract

Although adoptive T-cell therapy has been successful in hematological malignancy treatment, its application in solid tumors remains a great challenge. Here, using a pH-sensitive benzoic-imine bond and inverse electron-demand Diels-Alder cycloaddition, we prepared magnetic nanoclusters (NCs) armed with responsive PD-1 antibody (aP), which could then bind onto effector T cells due to their PD-1 expression. After adoptive transfer, the magnetization and superparamagnetism of NCs enabled us to magnetically recruit effector T cells and aP simultaneously to tumor sites with MRI guidance. Owing to the acidic intratumoral microenvironment, the benzoic-imine bond then hydrolyzed, leading to the release of aP. The therapeutic effects of adoptive T cells and free aP could thus be spatiotemporally coupled. As a result, we achieved inhibition of tumor growth with few side effects, demonstrating the great promise of such a chemical approach for safe and high-performance adoptive T-cell therapy against solid tumors.

摘要

虽然过继性 T 细胞疗法在血液恶性肿瘤的治疗中已取得成功,但它在实体瘤中的应用仍然是一个巨大的挑战。在这里,我们使用 pH 敏感的苯甲酸亚胺键和反向电子需求 Diels-Alder 环加成反应,制备了带有响应性 PD-1 抗体 (aP) 的磁性纳米团簇 (NCs),由于其 PD-1 的表达,NCs 可以结合到效应 T 细胞上。在过继转移后,NCs 的磁化和超顺磁性使我们能够在 MRI 引导下将效应 T 细胞和 aP 同时磁募集到肿瘤部位。由于肿瘤内酸性微环境,苯甲酸亚胺键随后发生水解,导致 aP 的释放。因此,过继 T 细胞和游离 aP 的治疗效果可以时空偶联。结果,我们实现了肿瘤生长的抑制,副作用很少,这表明这种化学方法在安全高效的针对实体瘤的过继性 T 细胞治疗方面具有巨大的应用前景。

相似文献

1
Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors.磁性纳米簇武装响应性 PD-1 抗体协同增强用于实体瘤的过继性 T 细胞疗法。
ACS Nano. 2019 Feb 26;13(2):1469-1478. doi: 10.1021/acsnano.8b07141. Epub 2019 Feb 18.
2
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.嵌合 PD-1:28 受体增强低亲和性 T 细胞,并恢复肿瘤浸润淋巴细胞的效应功能,用于过继细胞治疗。
Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22.
3
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.肿瘤酸度的中和可改善对免疫疗法的抗肿瘤反应。
Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30.
4
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.靶向 PIM 激酶联合 PD1 抑制增强免疫治疗抗肿瘤 T 细胞反应。
Clin Cancer Res. 2019 Feb 1;25(3):1036-1049. doi: 10.1158/1078-0432.CCR-18-0706. Epub 2018 Oct 16.
5
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.在致耐受性环境中,阻断程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)可促进过继性T细胞免疫疗法。
PLoS One. 2015 Mar 5;10(3):e0119483. doi: 10.1371/journal.pone.0119483. eCollection 2015.
6
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.程序性死亡蛋白1的阻断增强了经工程改造靶向NY-ESO-1的人T细胞在过继转移后控制肿瘤生长的能力。
Clin Cancer Res. 2016 Jan 15;22(2):436-47. doi: 10.1158/1078-0432.CCR-15-1070. Epub 2015 Aug 31.
7
Expansion of Tumor-Infiltrating CD8 T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.肿瘤浸润 CD8 T 细胞表达 PD-1 的扩增提高了过继性 T 细胞治疗的疗效。
Cancer Res. 2017 Jul 1;77(13):3672-3684. doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18.
8
T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.编码白细胞介素2和肿瘤坏死因子α的腺病毒介导的T细胞疗法可诱导自发性黑色素瘤小鼠的全身免疫调节。
J Immunother. 2016 Nov/Dec;39(9):343-354. doi: 10.1097/CJI.0000000000000144.
9
Adoptive cell therapy using PD-1 myeloma-reactive T cells eliminates established myeloma in mice.利用 PD-1 骨髓瘤反应性 T 细胞的过继细胞疗法可消除小鼠体内已建立的骨髓瘤。
J Immunother Cancer. 2017 Jun 20;5:51. doi: 10.1186/s40425-017-0256-z. eCollection 2017.
10
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.免疫疗法在原位扩展并维持高亲和力肿瘤浸润性CD8 T细胞的功能。
J Immunol. 2016 Sep 15;197(6):2509-21. doi: 10.4049/jimmunol.1502659. Epub 2016 Aug 8.

引用本文的文献

1
Smart CAR-T Nanosymbionts: archetypes and proto-models.智能嵌合抗原受体T细胞纳米共生体:原型与原始模型
Front Immunol. 2025 Aug 12;16:1635159. doi: 10.3389/fimmu.2025.1635159. eCollection 2025.
2
A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.纳米颗粒与嵌合抗原受体T细胞疗法联合应用的挑战与进展的文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2518634. doi: 10.1080/21645515.2025.2518634. Epub 2025 Jun 17.
3
Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases.
利用免疫疗法和仿生纳米疗法对高级别胶质瘤和脑转移瘤进行免疫反应重新校准。
Asian J Pharm Sci. 2025 Apr;20(2):101021. doi: 10.1016/j.ajps.2025.101021. Epub 2025 Jan 17.
4
Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.用于胶质母细胞瘤的生物工程化嵌合抗原受体T细胞/自然杀伤细胞疗法的进展:克服免疫抑制及基于纳米技术增强嵌合抗原受体T细胞/自然杀伤细胞疗法的策略
Bioeng Transl Med. 2024 Aug 31;10(2):e10716. doi: 10.1002/btm2.10716. eCollection 2025 Mar.
5
SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.合成生物学纳米设计:利用工程纳米材料开创靶向药物递送技术。
J Nanobiotechnology. 2025 Mar 6;23(1):178. doi: 10.1186/s12951-025-03254-9.
6
Enhancing immunotherapy with tumour-responsive nanomaterials.用肿瘤响应性纳米材料增强免疫疗法。
Nat Rev Clin Oncol. 2025 Apr;22(4):262-282. doi: 10.1038/s41571-025-01000-6. Epub 2025 Mar 6.
7
Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism.用磁性纳米颗粒加载CAR-T细胞以实现可控靶向,可抑制炎性细胞因子释放并改变肿瘤细胞死亡机制。
MedComm (2020). 2025 Jan 5;6(1):e70039. doi: 10.1002/mco2.70039. eCollection 2025 Jan.
8
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad.嵌合抗原受体T细胞纳米共生体:揭示一种新型二元组合的无限潜力。
Int J Mol Sci. 2024 Dec 7;25(23):13157. doi: 10.3390/ijms252313157.
9
Ultrasound-Activated Precise Sono-Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis.用于减少肺纤维化的乳腺癌超声激活精准 Sono 免疫疗法
Adv Sci (Weinh). 2025 Feb;12(5):e2407609. doi: 10.1002/advs.202407609. Epub 2024 Dec 16.
10
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.增强癌症治疗中抗 PD-1 抗体、抗 PD-L1 抗体和抗 CTLA-4 抗体治疗效果的策略。
J Transl Med. 2024 Aug 9;22(1):751. doi: 10.1186/s12967-024-05552-6.